

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Hodge et al.

**Application No.** 10/535,523

**Filed:** March 24, 2006

**Confirmation No.** 8826

**For:** CELL LINES AND HOST NUCLEIC ACID  
SEQUENCES RELATED TO INFECTIOUS  
DISEASE

**FILED VIA EFS**

**Examiner:** Agnieszka Boesen

**Art Unit:** 1648

**Attorney Reference No.** 6395-66741-06

FILED VIA EFS  
COMMISSIONER FOR PATENTS

**INFORMATION DISCLOSURE STATEMENT PURSUANT TO**  
**37 C.F.R. § 1.97(e)(1)**

Listed on the accompanying form PTO-1449 and submitted herewith are seven English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement (IDS) is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby states that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. As a result, no fee should be required to file this IDS.

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By                     /Karri Kuenzli Bradley/                      
Karri Kuenzli Bradley, Ph.D.  
Registration No. 56,300

cc: Docketing